{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:39:24Z","timestamp":1791607164057,"version":"4.3.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>\n                      Hepatic fibrosis secondary to HCV infection can lead to cirrhosis and hepatic decompensation. Sustained virologic response (SVR) is possible with direct\u2010acting antiviral drug regimens; however, patients with advanced fibrosis have an increased risk for HCC. Heat shock protein 47 (HSP47), a key collagen chaperone, has been implicated in fibrosis development. We evaluated the efficacy and safety of BMS\u2010986263, a lipid nanoparticle delivering small interfering RNA designed to degrade\n                      <jats:italic toggle=\"yes\">HSP47<\/jats:italic>\n                      mRNA, for the treatment of advanced fibrosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results<\/jats:title>\n                    <jats:p>NCT03420768 was a Phase 2, randomized (1:1:2), placebo\u2010controlled trial conducted at a hepatology clinic in the United States. Patients with HCV\u2010SVR (for \u2265 1 year) and advanced fibrosis received once\u2010weekly i.v. infusions of placebo or BMS\u2010986263 (45 or 90 mg) for 12 weeks. The primary endpoint was \u2265 1 METAVIR stage improvement at Week 12; key secondary endpoints included Ishak score improvement, pharmacokinetics, fibrosis biomarkers, and safety. All 61 patients completed treatment, and 2\/15 (13%, placebo), 3\/18 (17%, 45 mg), and 6\/28 (21%, 90 mg) had METAVIR improvements of \u2265 1 stage at Week 12. Five patients in the 90\u2010mg arm had Ishak improvements by \u2265 2 stages. BMS\u2010986263 plasma concentrations increased in a generally dose\u2010proportional fashion between BMS\u2010986263 doses, with no notable accumulation with weekly dosing. All adverse events (AEs) were mild or moderate in intensity; most treatment\u2010related AEs were infusion\u2010related reactions in the BMS\u2010986263 arms. At baseline, collagen levels were low, indicating low levels of fibrogenesis in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with HCV\u2010SVR, BMS\u2010986263 administration was generally well tolerated through Week 36 and resulted in METAVIR and Ishak score improvements. Further evaluation of BMS\u2010986263 in patients with active fibrogenesis is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.32181","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T23:41:18Z","timestamp":1633390878000},"page":"912-923","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":104,"title":["BMS\u2010986263 in patients with advanced hepatic fibrosis: 36\u2010week results from a randomized, placebo\u2010controlled phase 2 trial"],"prefix":"10.1097","volume":"75","author":[{"given":"Eric J.","family":"Lawitz","sequence":"first","affiliation":[{"name":"The Texas Liver Institute,University of Texas Health San Antonio,San Antonio,Texas,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"Shevell","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,Princeton,New Jersey,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridhar S.","family":"Tirucherai","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,Princeton,New Jersey,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Du","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,Princeton,New Jersey,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warner","family":"Chen","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,Princeton,New Jersey,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Kavita","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,Princeton,New Jersey,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie","family":"Coste","sequence":"additional","affiliation":[{"name":"The Texas Liver Institute,University of Texas Health San Antonio,San Antonio,Texas,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Poordad","sequence":"additional","affiliation":[{"name":"The Texas Liver Institute,University of Texas Health San Antonio,San Antonio,Texas,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Karsdal","sequence":"additional","affiliation":[{"name":"Nordic Bioscience,Herlev,Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Nordic Bioscience,Herlev,Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Goodman","sequence":"additional","affiliation":[{"name":"Inova Fairfax Hospital,Falls Church,Virginia,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar D.","family":"Charles","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,Princeton,New Jersey,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"hep32181-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"921","DOI":"10.12688\/f1000research.14841.1","article-title":"Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts","volume":"7","year":"2018","journal-title":"F1000Res"},{"key":"hep32181-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause\u2010specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi\u2010national cohort study","volume":"155","year":"2018","journal-title":"Gastroenterology"},{"key":"hep32181-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta\u2010analysis","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep32181-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/cid\/civ860","article-title":"All\u2010cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus","volume":"62","year":"2016","journal-title":"Clin Infect Dis"},{"key":"hep32181-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/apt.14204","article-title":"Effectiveness of 8\u2010 or 12\u2010weeks of ledipasvir and sofosbuvir in real\u2010world treatment\u2010naive, genotype 1 hepatitis C infected patients","volume":"46","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"hep32181-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/liv.14390","article-title":"Collagen biology and non\u2010invasive biomarkers of liver fibrosis","volume":"40","year":"2020","journal-title":"Liver Int"},{"key":"hep32181-bib-0009-20250824","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1074\/jbc.TM118.002812","article-title":"Roles of the endoplasmic reticulum\u2010resident, collagen\u2010specific molecular chaperone Hsp47 in vertebrate cells and human disease","volume":"294","year":"2019","journal-title":"J Biol Chem"},{"key":"hep32181-bib-0010-20250824","first-page":"452","article-title":"Matrix metalloproteinase functions in hepatic injury and fibrosis","volume":"68\u201369","year":"2018","journal-title":"Matrix Biol"},{"key":"hep32181-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.20425","article-title":"Antifibrotic effects of a tissue inhibitor of metalloproteinase\u20101 antibody on established liver fibrosis in rats","volume":"40","year":"2004","journal-title":"Hepatology"},{"key":"hep32181-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A\u2013coupled liposomes to deliver siRNA against a collagen\u2010specific chaperone","volume":"26","year":"2008","journal-title":"Nat Biotechnol"},{"key":"hep32181-bib-0013-20250824","first-page":"237A","article-title":"Clinical phase 1b\/2 study results for safety, pharmacokinetics, and efficacy of ND\u2010L02\u2010s0201, a novel targeted lipid nanoparticle (LNP) delivering HSP47 siRNA for the treatment of patients with advanced liver fibrosis","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep32181-bib-0014-20250824","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0168-8278(18)30442-2","article-title":"Safety, tolerability, and pharmacokinetics of BMS\u2010986263\/NDL02\u2010s0201, a novel targeted lipid nanoparticle delivering HSP47 siRNA, in healthy participants: a randomised, placebo\u2010controlled, double\u2010blind, phase 1 study","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep32181-bib-0015-20250824","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1172\/JCI117617","article-title":"Coexpression of the collagen\u2010binding stress protein HSP47 gene and the alpha 1(I) and alpha 1(III) collagen genes in carbon tetrachloride\u2010induced rat liver fibrosis","volume":"94","year":"1994","journal-title":"J Clin Invest"},{"key":"hep32181-bib-0016-20250824","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s004280050191","article-title":"Bleomycin\u2010induced pulmonary fibrosis in rat is associated with increased expression of collagen\u2010binding heat shock protein (HSP) 47","volume":"432","year":"1998","journal-title":"Virchows Arch"},{"key":"hep32181-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1136\/gutjnl-2013-305632","article-title":"Involvement of interleukin\u201017A\u2010induced expression of heat shock protein 47 in intestinal fibrosis in Crohn's disease","volume":"63","year":"2014","journal-title":"Gut"},{"key":"hep32181-bib-0018-20250824","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"hep32181-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nbt0408-399","article-title":"Targeting siRNA to arrest fibrosis","volume":"26","year":"2008","journal-title":"Nat Biotechnol"},{"key":"hep32181-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1007\/s00253-017-8433-z","article-title":"Therapeutic potentials of short interfering RNAs","volume":"101","year":"2017","journal-title":"Appl Microbiol Biotechnol"},{"key":"hep32181-bib-0021-20250824","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1053\/gast.2002.33367","article-title":"Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C","volume":"122","year":"2002","journal-title":"Gastroenterology"},{"key":"hep32181-bib-0022-20250824","first-page":"739A","article-title":"Safety, pharmacokinetics, and immunogenicity of BMS\u2010986263\/ND\u2010L02\u2010s0201 in healthy Japanese and non\u2010Japanese participants","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep32181-bib-0023-20250824","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1016\/S0168-8278(18)30701-3","article-title":"Clinical phase 1b study results for safety, pharmacokinetics and efficacy of ND\u2010L02\u2010s0201, a novel targeted lipid nanoparticle delivering HSP47 SIRNA for the treatment of Japanese patients with advanced liver fibrosis","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep32181-bib-0024-20250824","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/hep.29090","article-title":"Dual\u2010photon microscopy\u2010based quantitation of fibrosis\u2010related parameters (q\u2010FP) to model disease progression in steatohepatitis","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep32181-bib-0025-20250824","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1208\/s12248-019-0360-8","article-title":"A fit\u2010for\u2010purpose method for the detection of human antibodies to surface\u2010exposed components of BMS\u2010986263, a lipid nanoparticle\u2013based drug product containing a siRNA drug substance","volume":"21","year":"2019","journal-title":"AAPS J"},{"key":"hep32181-bib-0026-20250824","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of liver fibrosis: a translational success story","volume":"64","year":"2015","journal-title":"Gut"},{"key":"hep32181-bib-0027-20250824","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","article-title":"Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5\u2010year follow\u2010up of 150 patients","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"hep32181-bib-0028-20250824","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB\u20104 scores","volume":"157","year":"2019","journal-title":"Gastroenterology"},{"key":"hep32181-bib-0029-20250824","article-title":"Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and C","volume":"95","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"hep32181-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","year":"2018","journal-title":"Gastroenterology"},{"key":"hep32181-bib-0031-20250824","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/hep4.1228","article-title":"Morphometry confirms fibrosis regression from sustained virologic response to direct\u2010acting antivirals for hepatitis C","volume":"2","year":"2018","journal-title":"Hepatol Commun"},{"key":"hep32181-bib-0032-20250824","first-page":"911A","article-title":"Establishing the stability, precision, potential influencing factors and reference ranges of a biomarker of liver fibrosis, PRO\u2010C3, in healthy subjects, obese, and NAFLD patients [Abstract]","volume":"72","year":"2020","journal-title":"Hepatology"},{"key":"hep32181-bib-0033-20250824","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hepr.12331","article-title":"Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response","volume":"45","year":"2015","journal-title":"Hepatol Res"},{"key":"hep32181-bib-0034-20250824","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct\u2010acting antiviral agents","volume":"153","year":"2017","journal-title":"Gastroenterology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.32181","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.32181","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:44Z","timestamp":1756080044000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.32181","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"assertion":[{"value":"2021-05-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}